NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in Patients With Brain Metastases (BM) Article

Wefel, Jeffrey S, Pugh, Stephanie, Gondi, Vinai et al. (2019). NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in Patients With Brain Metastases (BM) . NEUROSURGERY, 66(Supplement 1), 310-642. 10.1093/neuros/nyz310_642

cited authors

  • Wefel, Jeffrey S; Pugh, Stephanie; Gondi, Vinai; Brown, Paul D; Tome, Wolfgang; Armstrong, Terri S; Bruner, Deborah; Bovi, Joseph; Robinson, Cliff; Khuntia, Deepak; Grosshans, David; Konski, Andre; Roberge, David; Kundapur, Vijayananda; Devisetty, Kiran; Shah, Sunjay; Usuki, Kenneth; Anderson, Bethany; Mehta, Minesh P; Kachnic, Lisa

authors

publication date

  • September 1, 2019

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 52 Psychology
  • 5202 Biological Psychology
  • Basic Behavioral and Social Science
  • Behavioral and Social Science
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Health Disparities
  • Mental Health
  • Minority Health
  • Neurosciences
  • Orphan Drug
  • Radiation Oncology
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Wolters Kluwer

start page

  • 310

end page

  • 642

volume

  • 66

issue

  • Supplement 1